GlassScriptPhysician profile
Rosa Espinosa
NPI 1821548629
$3,132.51
in general payments reported to CMS, 2019-2025
13 companies · $361 in 2025
The $361 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $338 · 2022: $1,750 · 2023: $630 · 2024: $54.04 · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $951 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $950.96 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $1,228.59 | 2022 | |
| Glaxosmithkline, LLC. | $382.60 | 2021-2025 | Jemperli, Zejula |
| Myriad Genetic Laboratories, INC. | $297.35 | 2021-2023 | Myrisk |
| Seagen INC. | $278.08 | 2022-2023 | Tivdak |
| Abbvie INC. | $222.92 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $148.00 | 2024-2025 | Lynparza |
| Merck Sharp & Dohme LLC | $138.99 | 2022-2023 | Keytruda, Lynparza |
| Astellas Pharma US INC | $126.41 | 2023 | Veozah |
| Immunogen, INC. | $119.19 | 2023 | Elahere |
| Ethicon US, LLC | $76.89 | 2021-2022 | |
| Daiichi Sankyo INC. | $58.91 | 2024-2025 | Enhertu |
| Sumitomo Pharma America, INC. | $37.42 | 2023-2025 | Myfembree, Gemtesa |
| Beone Medicines USA, INC. | $17.16 | 2025 | Tevimbra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosa Espinosa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.